IQVIA Holdings Inc. (IQV) Stock

IQVIA Holdings Inc. (IQV) is a Technology stock trading at $206.87 (as of 2026-07-15), with a market capitalization of $34.53B and a trailing P/E of 30.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

IQVIA Holdings Inc. provides analytics and technology solutions, research and development services, and contract sales and medical solutions to life sciences customers. It operates through Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, serving clients across the Americas, Europe, Africa, and Asia-Pacific.

Understand IQVIA Holdings Inc.: how it makes money

IQVIA provides advanced analytics, cloud-based technology solutions, and clinical research services to the life sciences industry, and it makes money by delivering technology and implementation services plus research, evidence, and contract sales and medical solutions.

IQVIA’s profit model is driven by its services mix across Research & Development Solutions and Technology and Analytics Solutions, both of which focus on generating and disseminating evidence that informs healthcare decisions.

Revenue by segment (latest quarter)
R&DS$2.3B
TAS$1.6B
CSMS$0.2B

Business quality (Mixed): Well-defined, reportable segment structure (R&DS, TAS, CSMS) tied to core life-sciences workflows, with operating margin reported at 12.4% for the period ended 2026-03-31.

Valuation: Trades at 21× trailing earnings · $28B market cap.

Bull case

  • Diversified service lines within life sciences: IQVIA operates three reportable segments, Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, serving life sciences customers across the Americas, Europe, Africa, and the Asia-Pacific.
  • Evidence-focused offerings: Technology & Analytics Solutions include real world solutions that enable customers to generate and disseminate evidence that informs healthcare decision making.

Bear case

  • Concentration risk across the largest segments: A large share of segment revenue comes from Research & Development Solutions and Technology & Analytics Solutions, so results may be sensitive to changes in those segments’ demand.
  • Smaller third segment contribution: Contract Sales & Medical Solutions is a smaller portion of segment revenue based on the provided segment value (0.21B).
Valuation — source: SEC EDGAR (first-party)
Price$206.87
Market Cap$34.53B
P/E Ratio30.8
EV / EBITDA15.2
Price / Book5.44
Price / Sales2.14
FCF Yield9.1%
DCF Value (model)$46.73
DCF Upside vs Price-77.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$16.31B
Net Margin8.3%
Revenue Growth (YoY)5.9%
EPS Growth (YoY)4.5%
FCF Growth (YoY)-3.0%
Financial Health — source: SEC EDGAR
Altman Z-Score1.95 (grey)
Valuation vs Sector & Industry
Stock P/E30.8
Sector P/E (Technology)34.5
Industry P/E (Business Services)30.8
vs Sector-10.7%
vs Industry0.0%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($4.43B)
Institutional Holders Tracked10
Congressional Trades (recent)10
Company
SectorTechnology
IndustryBusiness Services
CEOAri Bousbib
Employees89,000
CountryUS
IPO Date2013-05-09

Related Companies (Business model: Clinical Labs / CRO Services; 8 closest by market cap; US-domiciled)

  • Natera, Inc. (NTRA)
  • Quest Diagnostics Incorporated (DGX)
  • Labcorp Holdings Inc. (LH)
  • Guardant Health, Inc. (GH)
  • UL Solutions Inc. (ULS)
  • Medpace Holdings, Inc. (MEDP)
  • Charles River Laboratories International, Inc. (CRL)
  • Absci Corporation (ABSI)
IQV earnings history · IQV institutional & insider holders · IQV KPIs & operating metrics · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-07-15.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.